Cerebral Palsy, Spastic Paraplegia and Hemiparesis, Equine and Equinovarus Foot Deformation
Conditions
Brief summary
1. To assess the clinical and neurophysiological efficacy of Xeomin® vs. Botox® in children with spastic equine and equinovarus foot deformation in pediatric cerebral palsy 2. To assess the safety of Xeomin® use as compared to Botox® in this patient population
Interventions
DRUGXeomin
Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
DRUGBotox®
Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
Sponsors
LLC Merz Pharma, Russia
Merz Pharmaceuticals GmbH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
* Children from 2 through 12 years of age, of both sexes, suffering from spastic paraplegia or hemiparesis in pediatric cerebral palsy. * Equine and equinovarus foot posture. * Gastrocnemius spasticity of 2 points and greater, by modified Ashworth scale. * Patient can walk unassisted or with a support. * Mental development of patients is normal or mildly retarded. * Previous course of spasticity treatment with BTA products was completed earlier than at 6 months before this trial or never administered before. * Patient's parents have signed an informed consent, are able and wishing to adhere to procedures described in the trial protocol and to the schedule of visits throughout the entire period of treatment.
Exclusion criteria
* Fixed ankle joint contracture. * Previous denervation of spastic muscles by surgery, phenol or alcohol; * Athetosis and dystonia in the area of injected muscles. * Inflammation at the planned injection site. * Elevated body temperature and acute (infectious and non-infectious) diseases at the time of injection. * Neuromuscular transmission disorders (myasthenia gravis, Lambert-Eaton syndrome, etc.). * Decompensated physical diseases potentially affecting the trial findings. * Acute fever, infection or surgery within 1 month before the trial. * Use of aminoglycosides or spectinomycin within 1 month before starting the trial. * Hypersensitivity to any of product ingredients. * Positive history for allergies (especially with regard to protein-containing products). * Patient's parents are unable or unwilling to adhere to the trial protocol requirements including signing the informed consent and conforming to the schedule of visits. * Participation in other clinical trials in the last 4 weeks before inclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline in the degree of spasticity in gastrocnemius according to modified Ashworth scale (AS) | From baseline to day 30 | The AS is a well known and commonly used scale in clinical trials with spasticity. In spastic muscles the resistance to passive movement is assessed. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of decrease in M-response magnitude and area recorded from the lateral and medial gastrocnemius heads, from baseline values | From baseline up to day 90 | Electromyography: The amplitude of a compound muscle action potential (M-wave) is recorded. An electrical stimulation is considered supramaximal when the M-wave amplitude no longer increases while increasing the stimulus. The measurements include the M-wave amplitude and the negative peak area of the M-wave. |
| Changes from baseline in the ratio of M-response recorded from the lateral and medial gastrocnemius heads and from tibialis anterior | From baseline up to day 90 | — |
| Changes from baseline in patient percentage in groups by the degree of gastrocnemius spasticity according to modified Ashworth scale | From baseline up to day 90 | — |
| Changes from baseline in motor activity according to Gross Motor Function Classification Systems (GMFCS) criteria | From baseline up to day 90 | GMFCS is a 5-level classification system that is a standardized observational instrument for children with CP developed to measure change in gross motor function over time. |
| Changes from baseline in the degree of spasticity in gastrocnemius according to modified Ashworth scale | Baseline up to day 90 | — |
| Changes from baseline in angles and angle ratio of ankle joints at passive and voluntary extension | From baseline up to day 90 | — |
Countries
Russia
Outcome results
None listed